These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32301258)

  • 41. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report.
    Tanimine N; Ide K; Yamashita M; Tanaka Y; Igarashi Y; Banshodani M; Tazawa H; Basnet NB; Doskali M; Onoe T; Tashiro H; Ohdan H
    Transplant Proc; 2011; 43(6):2411-4. PubMed ID: 21839279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful renal transplantation with desensitization in highly sensitized patients: a single center experience.
    Yoon HE; Hyoung BJ; Hwang HS; Lee SY; Jeon YJ; Song JC; Oh EJ; Park SC; Choi BS; Moon IS; Kim YS; Yang CW
    J Korean Med Sci; 2009 Jan; 24 Suppl(Suppl 1):S148-55. PubMed ID: 19194545
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Phase I/II Trial of the Interleukin-6 Receptor-Specific Humanized Monoclonal (Tocilizumab) + Intravenous Immunoglobulin in Difficult to Desensitize Patients.
    Vo AA; Choi J; Kim I; Louie S; Cisneros K; Kahwaji J; Toyoda M; Ge S; Haas M; Puliyanda D; Reinsmoen N; Peng A; Villicana R; Jordan SC
    Transplantation; 2015 Nov; 99(11):2356-63. PubMed ID: 26018350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Desensitization Before Living Donor Kidney Transplantation in Highly HLA-Sensitized Patients: A Single-Center Study.
    De Sousa-Amorim E; Revuelta I; Blasco M; Diekmann F; Cid J; Lozano M; Sánchez-Escuredo A; Martorell J; Palou E; Campistol JM; Oppenheimer F
    Transplant Proc; 2015 Oct; 47(8):2332-5. PubMed ID: 26518919
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia.
    Hansen RJ; Balthasar JP
    Blood; 2002 Sep; 100(6):2087-93. PubMed ID: 12200371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-HLA antibody repertoire after IVIg infusion in highly sensitized patients waiting for kidney transplantation.
    Ferrari-Lacraz S; Aubert V; Buhler L; Pascual M; Andresen I; Binet I; Martin PY; Villard J
    Swiss Med Wkly; 2006 Oct; 136(43-44):696-702. PubMed ID: 17183432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Desensitization in kidney transplantation: review and future perspectives.
    Abu Jawdeh BG; Cuffy MC; Alloway RR; Shields AR; Woodle ES
    Clin Transplant; 2014 Apr; 28(4):494-507. PubMed ID: 24621089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.
    Vo AA; Huang E; Ammerman N; Toyoda M; Ge S; Haas M; Zhang X; Peng A; Najjar R; Williamson S; Myers C; Sethi S; Lim K; Choi J; Gillespie M; Tang J; Jordan SC
    Am J Transplant; 2022 Apr; 22(4):1133-1144. PubMed ID: 34910841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG.
    Song S; Crow AR; Freedman J; Lazarus AH
    Blood; 2003 May; 101(9):3708-13. PubMed ID: 12506021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
    Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
    Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab.
    Vo AA; Petrozzino J; Yeung K; Sinha A; Kahwaji J; Peng A; Villicana R; Mackowiak J; Jordan SC
    Transplantation; 2013 Mar; 95(6):852-8. PubMed ID: 23511212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.
    Hansen RJ; Balthasar JP
    J Pharm Sci; 2003 Jun; 92(6):1206-15. PubMed ID: 12761810
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute antibody-mediated rejection of the kidney transplant - experience of a single center in Croatia.
    Orlić L; Sladoje-Martinović B; Mikolašević I; Pavletić Peršić M; Bubić I; Jelić I; Rački S
    Med Glas (Zenica); 2014 Feb; 11(1):138-44. PubMed ID: 24496355
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
    Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
    Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient.
    Dashti-Khavidaki S; Shojaie L; Hosni A; Khatami MR; Jafari A
    Nephrourol Mon; 2015 May; 7(3):e27073. PubMed ID: 26034746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients.
    Bollée G; Anglicheau D; Loupy A; Zuber J; Patey N; Mac Gregor D; Martinez F; Mamzer-Bruneel MF; Snanoudj R; Thervet E; Legendre C; Noël LH
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1461-8. PubMed ID: 18525007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.
    Viglietti D; Gosset C; Loupy A; Deville L; Verine J; Zeevi A; Glotz D; Lefaucheur C
    Am J Transplant; 2016 May; 16(5):1596-603. PubMed ID: 26693703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of action of intravenous immune globulin in immune-mediated diseases.
    Mouthon L; Kaveri SV; Spalter SH; Lacroix-Desmazes S; Lefranc C; Desai R; Kazatchkine MD
    Clin Exp Immunol; 1996 May; 104 Suppl 1():3-9. PubMed ID: 8625540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
    Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
    Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.